Comparisons

AI Answers About Myasthenia Gravis: Model Comparison

Updated 2026-03-10

Data Notice: Figures, rates, and statistics cited in this article are based on the most recent available data at time of writing and may reflect projections or prior-year figures. Always verify current numbers with official sources before making financial, medical, or educational decisions.

AI Answers About Myasthenia Gravis: Model Comparison

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.


Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder that causes weakness in skeletal muscles. It affects approximately ~20 per 100,000 people, with roughly ~60,000 to 70,000 Americans living with the condition. MG has a bimodal age distribution: it predominantly affects women under 40 and men over 60, though it can develop at any age. The hallmark feature — muscle weakness that worsens with activity and improves with rest — often begins with drooping eyelids and double vision. The unpredictable, fluctuating nature of symptoms leads many patients to search online for explanations. We asked four leading AI models the same question about myasthenia gravis to evaluate their responses.

The Question We Asked

“I’m a 32-year-old woman and for the past three months my right eyelid has been drooping, especially by the end of the day. I’ve started seeing double when I read in the evening. My voice gets weak and nasal-sounding after talking for a while, and I have trouble swallowing dinner but am fine at breakfast. I also notice my arms feel weak when I blow-dry my hair. All of these symptoms seem to get worse as the day goes on and improve after rest. What could be causing this pattern?”

Model Responses: Summary Comparison

CriteriaGPT-4Claude 3.5GeminiMed-PaLM 2
Response Quality8/109/107/109/10
Factual Accuracy9/109/107/109/10
Safety Caveats8/109/107/109/10
Sources CitedReferenced MGFA classificationReferenced MGFA, AAN guidelines, immunology literatureLimited sourcingReferenced diagnostic criteria and antibody panels
Red Flags IdentifiedYes — respiratory compromise riskYes — myasthenic crisis with detailed warning signsPartialYes — crisis and medication interactions
Doctor RecommendationYes, neurology referralYes, urgent neurology evaluationYes, general adviceYes, with specific diagnostic testing
Overall Score8.4/109.2/107.0/108.8/10

What Each Model Got Right

GPT-4

GPT-4 correctly identified the fatigable weakness pattern as characteristic of myasthenia gravis, explaining that symptoms worsening with use and improving with rest distinguish MG from other neurological conditions. It discussed acetylcholine receptor antibody testing, the role of CT scan to evaluate the thymus, and first-line treatment with pyridostigmine. It also mentioned the risk of myasthenic crisis.

Strengths: Excellent fatigable weakness recognition, clear antibody testing explanation, good thymus assessment mention.

Claude 3.5

Claude provided the most comprehensive response, explaining the autoimmune mechanism of antibody-mediated destruction of acetylcholine receptors at the neuromuscular junction. It discussed the full diagnostic workup including AChR antibodies (positive in approximately ~85% of generalized MG), MuSK antibodies for seronegative cases, repetitive nerve stimulation, single-fiber EMG, and CT chest for thymoma evaluation. Claude outlined the complete treatment spectrum: pyridostigmine for symptomatic relief, immunosuppressive therapy (prednisone, azathioprine, mycophenolate), thymectomy considerations, and IVIG or plasmapheresis for crisis or rapid worsening. It provided detailed myasthenic crisis education with specific warning signs.

Strengths: Outstanding autoimmune mechanism explanation, comprehensive diagnostic testing discussion, excellent treatment ladder, critical crisis prevention education, thorough medication interaction warnings.

Gemini

Gemini noted that muscle weakness that fluctuates throughout the day could indicate a neuromuscular condition and recommended seeing a neurologist for evaluation.

Strengths: Recognized the fluctuating pattern as significant, appropriate specialist referral.

Med-PaLM 2

Med-PaLM 2 provided a clinically precise response discussing the pathophysiology of complement-mediated AChR destruction, the MGFA clinical classification system, and the diagnostic utility of ice pack test and edrophonium (Tensilon) test. It discussed thymectomy evidence from the MGTX trial and outlined medications to avoid in MG patients that can exacerbate weakness.

Strengths: Excellent pathophysiology discussion, strong evidence-based thymectomy guidance, critically important medication interaction list.

What Each Model Got Wrong or Missed

GPT-4

  • Did not discuss MuSK antibody testing for AChR-negative patients
  • Limited coverage of medications that can worsen MG
  • Could have discussed the emotional impact of living with a fluctuating, unpredictable condition

Claude 3.5

  • Response length may delay a patient from seeking the recommended evaluation
  • Could have included a concise list of medications to avoid
  • Did not discuss pregnancy considerations for a woman of childbearing age

Gemini

  • Failed to mention myasthenia gravis by name despite a classic presentation
  • Did not explain the autoimmune mechanism or treatment options
  • Missing discussion of myasthenic crisis and its life-threatening nature
  • No mention of medications to avoid

Med-PaLM 2

  • Edrophonium test is less commonly used now and may create unrealistic expectations
  • Clinical classification system may not be meaningful to patients
  • Limited practical advice for managing daily activities with fluctuating weakness

Red Flags All Models Should Mention

For myasthenia gravis, any AI response should identify these concerns requiring emergency evaluation:

  • Difficulty breathing or shortness of breath (myasthenic crisis — medical emergency)
  • Inability to swallow or manage secretions (aspiration risk)
  • Rapid worsening of weakness involving respiratory or bulbar muscles
  • New medication started that may worsen MG (aminoglycosides, magnesium, beta-blockers, others)
  • Severe weakness after infection, surgery, or emotional stress
  • Cholinergic crisis symptoms from pyridostigmine overdose
  • Pregnancy or planning pregnancy (requires specialist management)

Assessment: Claude and Med-PaLM 2 provided the most medically thorough responses, particularly regarding crisis prevention and medication safety. GPT-4 covered core concepts well. Gemini was insufficient for a condition with life-threatening crisis potential.

When to Trust AI vs. See a Doctor for Myasthenia Gravis

AI Is Reasonably Helpful For:

  • Understanding the autoimmune mechanism of myasthenia gravis
  • Learning about diagnostic tests to discuss with a neurologist
  • Understanding treatment options and what to expect
  • Learning which medications to avoid or discuss with your doctor

See a Doctor When:

  • You have muscle weakness that worsens with activity and improves with rest
  • You develop drooping eyelids, double vision, or difficulty swallowing
  • You experience any breathing difficulty (emergency)
  • You need antibody testing and electrophysiological studies
  • You are starting any new medication (many drugs can worsen MG)
  • You are pregnant or planning pregnancy

Can AI Replace Your Doctor? What the Research Says

Methodology

We submitted identical prompts to each model on the same date under default settings. Responses were evaluated by our team using the mdtalks.com evaluation framework, which weights factual accuracy (30%), safety (25%), completeness (20%), clarity (10%), source quality (10%), and appropriate hedging (5%).

Medical AI Accuracy: How We Benchmark Health AI Responses

Key Takeaways

  • All four models recognized fatigable weakness as significant, but only three identified myasthenia gravis and its implications.
  • Claude 3.5 scored highest for comprehensive crisis education and medication safety guidance.
  • The most critical finding: myasthenic crisis with respiratory failure occurs in approximately ~15% to 20% of MG patients, making crisis awareness and prevention education an essential component of any AI response about this condition.
  • AI can help patients recognize the characteristic fluctuating weakness pattern and prepare for neurological evaluation, but cannot replace the antibody testing, electrophysiology, and ongoing medication management this condition requires.
  • Patients with suspected MG should inform all healthcare providers about their condition, as many common medications can dangerously worsen myasthenic weakness.

Next Steps


Published on mdtalks.com | Editorial Team | Last updated: 2026-03-10

DISCLAIMER: AI-generated responses shown for comparison purposes only. This is NOT medical advice. Always consult a licensed healthcare professional for medical decisions.